INTERVIEW: Tackling Asia’s Oncology Access Hurdles
This article was originally published in PharmAsia News
Industry may be doing its part to develop novel and effective cancer therapies, but one major multinational sees room for further regulatory improvements and partnerships to help ensure earlier and broader access to new drugs.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.